Humanin Dosage Guide

Dosage overview

Dosing notes

Humanin is primarily studied in preclinical settings (cell culture and animal models). A synthetic analog called HNG (S14G-humanin) has shown enhanced potency in research. No human clinical trials have established dosing protocols. Circulating humanin levels decline with age, which has prompted interest in supplementation, but delivery methods and dosing remain entirely experimental. Intranasal and subcutaneous routes have been used in animal studies.

Important safety information

Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.

• Start at the lowest effective dose and titrate up gradually
• Monitor for side effects, especially during dose increases
• Do not exceed researched dose ranges without medical supervision
• This is a research compound — human dosing guidelines are not FDA-established

Research references

• Humanin, a newly identified neuroprotective factor — Journal of Biological Chemistry (2001) [PubMed]
• The mitochondrial-derived peptide humanin activates the ERK1/2, AKT, and STAT3 signaling pathways — Journal of Biological Chemistry (2009) [PubMed]
• Humanin and age-related diseases: a new link? — Frontiers in Endocrinology (2018) [PubMed]
• Mitochondrial-derived peptide humanin improves insulin sensitivity — American Journal of Physiology (2014) [PubMed]
• Circulating levels of humanin in centenarians — Aging Cell (2020) [PubMed]
• Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans — Scientific Reports (2018) [PubMed]